A Phase 2/3 interventional study of Navepegritide (TransCon CNP) and Placebo for Navepegritide (TransCon CNP) in Achondroplasia, sponsored by Ascendis Pharma Growth Disorders A/S. Completed at 10 sites in 7 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Ascendis Pharma Growth Disorders A/S · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Achondroplasia with a site in United States — 8 open to participants now, 11 under way, 3 of them phase 3. Achondroplasia · United States.
Among the 29 studies in Achondroplasia with a site in United States, this one is the 8th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2023, is one of 3 in phase 2/3, and was the 21st registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →8 of the 29 studies in Achondroplasia with a site in United States are open now. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States, Australia, Canada and 6 more countries
Ages 2–17
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 4 more countries
Ages 0 yrs–32 mo
Tyra Biosciences, Inc · Sites in United States, Australia, Canada and 5 more countries
Ages 3–10
Ascendis Pharma A/S · Sites in United States, Australia, Austria and 12 more countries
Ages 0–2
BioMarin Pharmaceutical · Sites in United States
Ages 0 mo–18 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 6
First in 1996; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 76 across the 20 interventional studies, 271 across the 9 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 9 most frequent:
Ascendis Pharma Growth Disorders A/S is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Ascendis Pharma Growth Disorders A/S has 3 studies filed under Achondroplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Achondroplasia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial was to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of 100 µg TransCon CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia. The double-blind, placebo-controlled treatment period was followed by an Open Label Extension (OLE) period of a 52-week duration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known history of any bone-related surgery affecting growth potential of long bones, such as:
findings at Screening, such as:
Had a clinically significant finding or arrhythmia as determined by the investigator in consultation with the medical monitor that indicates abnormal cardiac function or conduction that includes, but was not exclusive to:
Known history or presence of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Navepegritide (TransCon CNP) 100 micrograms per kilogram (µg/kg) delivered once weekly by subcutaneous injection for a treatment period of up to 52 weeks.
Drug: Navepegritide (TransCon CNP)
Participants received placebo matched for Navepegritide (TransCon CNP) 100 µg/kg delivered once weekly by subcutaneous injection for a treatment period of up to 52 weeks.
Drug: Placebo for Navepegritide (TransCon CNP)
Participants who completed the 52-week treatment period continued into the open-label extension period and received treatment with navepegritide (TransCon CNP) doses up to Week 104. All participants received navepegritide at a dose of 100 μg/kg/week.
Drug: Navepegritide (TransCon CNP)
Once-weekly subcutaneous injection of 100 µg/kg Navepegritide (TransCon CNP)
Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide (TransCon CNP)
Annualized Growth Velocity (AGV) at Week 52
Annualized growth velocity is defined as (height - baseline height)/(date of height assessment - date of baseline) \* 365.25. Annualized growth velocity reported in terms of centimeters (cm) per year. Missing values at Week 52 were imputed by a multiple imputation method.
Time frame: At Week 52
Change From Baseline in Height Z-score (ACH-specific) at Week 52
ACH specific Z-scores of height provide a measure of growth relative to other individuals with ACH from the CLARITY database. A height Z-score is a standardized height measure after considering important factors like age and gender. Z-scores (or standard deviation scores) describe how far the measurement deviates from the mean. A height Z-score of 0 indicates that height is equal to the mean in the reference population. Negative numbers indicate values below the mean and positive numbers indicate values above the mean.
Time frame: Baseline, Week 52
Change From Baseline in Height Z-score (CDC-Based) at Week 52
Z-scores of height are determined using Centers for Disease Control and Prevention (CDC) clinical growth charts for children. A height Z-score is a standardized height measure after considering important factors like age and gender. Z-scores (or standard deviation scores) describe how far the measurement deviates from the median. A height Z-score of 0 indicates that height is equal to the median in the reference population. Negative numbers indicate values below the median and positive numbers indicate values above the median.
Time frame: Baseline, Week 52
| Milestone | Navepegritide | Placebo for Navepegritide | Open-Label Extension Period: Navepegritide |
|---|---|---|---|
| Started | 57 | 27 | 0 |
| Completed | 55 | 27 | 0 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 2 | 0 | 0 |
| Milestone | Navepegritide | Placebo for Navepegritide | Open-Label Extension Period: Navepegritide |
|---|---|---|---|
| Started | 0 | 0 | 82 |
| Completed | 0 | 0 | 80 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 1 |
Annualized growth velocity is defined as (height - baseline height)/(date of height assessment - date of baseline) \* 365.25. Annualized growth velocity reported in terms of centimeters (cm) per year. Missing values at Week 52 were imputed by a multiple imputation method.
| centimeters per year | Navepegritide | Placebo for Navepegritide |
|---|---|---|
| Annualized Growth Velocity (AGV) at Week 52 | 5.89 (5.66 to 6.13) | 4.41 (4.04 to 4.77) |
ACH specific Z-scores of height provide a measure of growth relative to other individuals with ACH from the CLARITY database. A height Z-score is a standardized height measure after considering important factors like age and gender. Z-scores (or standard deviation scores) describe how far the measurement deviates from the mean. A height Z-score of 0 indicates that height is equal to the mean in the reference population. Negative numbers indicate values below the mean and positive numbers indicate values above the mean.
| Z-score | Navepegritide | Placebo for Navepegritide |
|---|---|---|
| Change From Baseline in Height Z-score (ACH-specific) at Week 52 | 0.30 (0.24 to 0.35) | 0.01 (-0.07 to 0.10) |
Z-scores of height are determined using Centers for Disease Control and Prevention (CDC) clinical growth charts for children. A height Z-score is a standardized height measure after considering important factors like age and gender. Z-scores (or standard deviation scores) describe how far the measurement deviates from the median. A height Z-score of 0 indicates that height is equal to the median in the reference population. Negative numbers indicate values below the median and positive numbers indicate values above the median.
| Z-score | Navepegritide | Placebo for Navepegritide |
|---|---|---|
| Change From Baseline in Height Z-score (CDC-Based) at Week 52 | 0.15 (0.05 to 0.25) | -0.15 (-0.27 to -0.03) |
Collected over From Week 0 to Week 52 for double-blind treatment period and from Week 52 up to Week 104 for the Open Label Extension period (OLE) period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Navepegritide | 0/57 (0%) | 3/57 (5.3%) | 52/57 (91.2%) |
| Placebo for Navepegritide | 0/27 (0%) | 3/27 (11.1%) | 25/27 (92.6%) |
| Open-Label Extension Period: Navepegritide | 0/82 (0%) | 0/82 (0%) | 71/82 (86.6%) |
| Event | Navepegritide | Placebo for Navepegritide | Open-Label Extension Period: Navepegritide |
|---|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/57 | 1/27 | 0/82 |
| Mesenteric lymphadenitisBlood and lymphatic system disorders | 0/57 | 1/27 | 0/82 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/57 | 1/27 | 0/82 |
| TorticollisMusculoskeletal and connective tissue disorders | 1/57 | 0/27 | 0/82 |
| Vertebral foraminal stenosisMusculoskeletal and connective tissue disorders | 1/57 | 0/27 | 0/82 |
| Localised infectionInfections and infestations | 1/57 | 0/27 | 0/82 |
| Event | Navepegritide | Placebo for Navepegritide | Open-Label Extension Period: Navepegritide |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 18/57 | 10/27 | 23/82 |
| PyrexiaGeneral disorders | 20/57 | 6/27 | 17/82 |
| Otitis mediaInfections and infestations | 14/57 | 7/27 | 17/82 |
| Upper respiratory tract infectionInfections and infestations | 11/57 | 3/27 | 11/82 |
| VomitingGastrointestinal disorders | 11/57 | 3/27 | 7/82 |
| HeadacheNervous system disorders | 10/57 | 3/27 | 11/82 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/57 | 4/27 | 4/82 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 8/57 | 3/27 | 3/82 |
| Ear infectionInfections and infestations | 7/57 | 1/27 | 3/82 |
| FallInjury, poisoning and procedural complications | 7/57 | 3/27 | 7/82 |
Analysis was performed on full analysis set that included all randomized participants who have received at least one dose of investigational medicinal product (IMP) and have a non-missing baseline height as well as at least one post-baseline height measurement.
| Age, Continuous(years) | Navepegritide | Placebo for Navepegritide | Total |
|---|---|---|---|
| Mean | 5.56 ± 2.608 | 5.95 ± 2.748 | 5.68 ± 2.644 |
| Sex: Female, Male(Participants) | Navepegritide | Placebo for Navepegritide | Total |
|---|---|---|---|
| Female | 26 | 13 | 39 |
| Male | 31 | 14 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Navepegritide | Placebo for Navepegritide | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 6 |
| Not Hispanic or Latino | 52 | 25 | 77 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Navepegritide | Placebo for Navepegritide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 52 | 22 | 74 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Height(centimeter) | Navepegritide | Placebo for Navepegritide | Total |
|---|---|---|---|
| Mean | 88.82 ± 12.871 | 89.10 ± 11.450 | 88.98 ± 12.363 |
| CDC-Based Height Z-score(Z-score) | Navepegritide | Placebo for Navepegritide | Total |
|---|---|---|---|
| Median | -4.87 ± 0.976 | -5.24 ± 0.932 | -5.02 ± 0.968 |
| Achondroplasia (ACH)-specific Height Z-score(Z-score) | Navepegritide | Placebo for Navepegritide | Total |
|---|---|---|---|
| Mean | 0.18 ± 0.921 | -0.11 ± 0.725 | 0.09 ± 0.869 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Not planned
Ran from Mar 2023 to primary completion in Aug 2024, 17 months.
Results were first posted in Jul 2026, 1 year 11 months after primary completion. A results delay was requested in Aug 2025.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Navepegritide
Ascendis Pharma Growth Disorders A/S